KEYNOTE-010, a phase 2/3 RCT, evaluated the efficacy of single-agent pembrolizumab in previously treated patients with PD-L1 positive (≥1%) advanced NSCLC, regardless of histology. The gene discussed is CD274; the disease is non-small cell lung carcinoma.